Unit:
Speciality Myoskeletal Oncology: Diagnosis-Treatment-ResearchLibrary of the School of Health Sciences
Author:
Dimitriadou Areti
Supervisors info:
Ψυρρή Αδαμαντία, Καθηγήτρια, Ιατρικής Σχολής, ΕΚΠΑ
Κυριαζόγλου Αναστάσιος, Εντεταλμένος Διδάσκοντας, Ιατρικής Σχολής, ΕΚΠΑ
Αλεβιζόπουλος Νεκτάριος, Επισκέπτης Ερευνητής, Ιατρικής Σχολής, ΕΚΠΑ
Original Title:
Το Avapritinib ως νέα θεραπευτική επιλογή έναντι των μεσεγχυματικών στρωματικών όγκων του γαστρεντερικού συστήματος (Gastrointestinal Stromal Tumors, GIST’s)
Translated title:
Avapritinib as a new treatment option against Gastrointestinal Stromal Tumors (GIST's)
Summary:
Gastrointestinal stromal tumors (GIST’s) are rare neoplasms that concern about 5% of soft tissue sarcomas and have been classified as discrete neoplasms since 1990. They are found throughout the gastrointestinal system, mainly the stomach and small intestine, while they arise from other sites less frequently. These tumors carry mutations in the tyrosine kinase signaling pathway, mainly through KIT (CD117) and the platelet-derived growth factor receptor alpha (PDGFRA) gene. Symptoms vary from asymptomatic, to the appearance of anemia, gastrointestinal bleeding, pressure phenomena and others. Depending on the staging, the treatment includes a surgical approach based to criteria and chemotherapy. The cornerstone of chemotherapy is the tyrosine kinase inhibitors with imatinib as the first line. Due to drug resistance, other inhibitors with varying potency have been approved. The action of avapritinib as a selective treatment against exon 18 D842V mutations of the PDGFRA gene stands out, where it shows a significant clinical response.
Main subject category:
Health Sciences
Keywords:
Avapritinib, Treatment option, Gastrointestinal stromal tumors, GIST’s, CD117, PDGFRA
